LTGO — Latigo Biotherapeutics
Median target
$50
calls from the last 12 months
Implied return
+108.9%
median target vs. price
Coverage
2 analysts · 2 calls
updated in the last 12 months
Consensus
2/0/0+2 net
Buy / Hold / Sell
Which analysts are behind LTGO's consensus?
See every current rating, price target and the analysts' track records for Latigo Biotherapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 2 analysts with calls on LTGO updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
LTGO elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-10 | Insiders | Tananbaum James B.Director | Insider purchase | 140.0K sh @ $18.00 | $2.5M |
| 2026-08-10 | Insiders | Foresite Capital Management V, +510% owner | Insider purchase | 140.0K sh @ $18.00 | $2.5M |
More: insider activity · executive branch · trending